ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Romano-Ward Long QT Syndrome
Gene/Gene Panel: KCNQ1, KCNH2, SCN5A
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
1.0.3
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
KCNQ1 ⇔ 0100316 LONG QT SYNDROME 1; LQT1
Strong Actionability
Strong Actionability
KCNH2 ⇔ 0013367 LONG QT SYNDROME 2; LQT2
Strong Actionability
Strong Actionability
SCN5A ⇔ 0011377 LONG QT SYNDROME 3; LQT3
Strong Actionability
Strong Actionability
2022/02/09
Released (Under revision)
1.0.2
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
Obsolete MONDO ID was updated
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
KCNQ1 ⇔ 0100316 LONG QT SYNDROME 1; LQT1
Strong Actionability
Strong Actionability
KCNH2 ⇔ 0013367 LONG QT SYNDROME 2; LQT2
Strong Actionability
Strong Actionability
SCN5A ⇔ 0011377 LONG QT SYNDROME 3; LQT3
Strong Actionability
Strong Actionability
2021/09/16
Released
1.0.2
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
Obsolete MONDO ID was updated
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
KCNQ1 ⇔ 0100316 LONG QT SYNDROME 1; LQT1
Strong Actionability
Strong Actionability
KCNH2 ⇔ 0013367 LONG QT SYNDROME 2; LQT2
Strong Actionability
Strong Actionability
SCN5A ⇔ 0011377 LONG QT SYNDROME 3; LQT3
Strong Actionability
Strong Actionability
2021/09/16
Released (Under revision)
1.0.1
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
KCNQ1 ⇔ 0008646 LONG QT SYNDROME 1; LQT1
Strong Actionability
Strong Actionability
KCNH2 ⇔ 0013367 LONG QT SYNDROME 2; LQT2
Strong Actionability
Strong Actionability
SCN5A ⇔ 0011377 LONG QT SYNDROME 3; LQT3
Strong Actionability
Strong Actionability
2021/03/29
Released
1.0.1
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
KCNQ1 ⇔ 0008646 LONG QT SYNDROME 1; LQT1
Strong Actionability
Strong Actionability
KCNH2 ⇔ 0013367 LONG QT SYNDROME 2; LQT2
Strong Actionability
Strong Actionability
SCN5A ⇔ 0011377 LONG QT SYNDROME 3; LQT3
Strong Actionability
Strong Actionability
2020/12/16
Released (Under revision)
1.0.0
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
2020/05/01
Released
1.0.0
P
Sudden cardiac death (GroupB)
Avoidance of QT-prolonging medications (GroupB) 11CN
Beta blockers (GroupB) 10CA
Sudden cardiac death (GroupA)
Avoidance of QT-prolonging medications (GroupA) 10CN
Beta blockers (GroupA) 11CA
2019/12/09
In Preparation
N/A
¤ Powered by BCM's Genboree.